Annual and transition report of foreign private issuers pursuant to Section 13 or 15(d)

Segment Information (Tables)

v3.22.1
Segment Information (Tables)
12 Months Ended
Dec. 31, 2021
Disclosure of operating segments [abstract]  
Summary of making decisions regarding the allocation of resources and to assess performance

The criteria applied to identify the operating segments are consistent with the information reviewed by the Chief Executive Officer (the Group’s “Chief Operating Decision Maker”) in making decisions regarding the allocation of resources and to assess performance.

 

 

 

As at and for the year ended December 31, 2021

 

(EUR thousand)

 

Biopharmaceutical
and Diagnostic
Solutions

 

 

Engineering

 

 

Total
segments

 

 

Adjustments,
eliminations
and
unallocated
items

 

 

Consolidated

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

External Customers

 

 

694,038

 

 

 

149,882

 

 

 

843,920

 

 

 

 

 

 

843,920

 

Inter-Segment

 

 

1,134

 

 

 

68,979

 

 

 

70,113

 

 

 

(70,113

)

 

 

 

Total Revenues

 

 

695,172

 

 

 

218,861

 

 

 

914,033

 

 

 

(70,113

)

 

 

843,920

 

Cost of Sales

 

 

465,304

 

 

 

176,604

 

 

 

641,908

 

 

 

(63,393

)

 

 

578,515

 

Gross Profit

 

 

229,868

 

 

 

42,257

 

 

 

272,125

 

 

 

(6,720

)

 

 

265,405

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Other operating income

 

 

9,386

 

 

 

 

 

 

9,386

 

 

 

 

 

 

9,386

 

Selling and Marketing expenses

 

 

7,736

 

 

 

3,196

 

 

 

10,932

 

 

 

9,516

 

 

 

20,448

 

Research and Development expenses

 

 

23,467

 

 

 

4,263

 

 

 

27,730

 

 

 

1,886

 

 

 

29,616

 

General and Administrative expenses

 

 

58,996

 

 

 

11,898

 

 

 

70,894

 

 

 

(8,392

)

 

 

62,502

 

Operating Profit

 

 

149,055

 

 

 

22,900

 

 

 

171,955

 

 

 

(9,730

)

 

 

162,225

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total assets

 

 

885,733

 

 

 

253,767

 

 

 

1,139,500

 

 

 

279,342

 

 

 

1,418,842

 

Total liabilities

 

 

335,919

 

 

 

163,661

 

 

 

499,580

 

 

 

77,603

 

 

 

577,183

 

 

 

 

 

As at and for the year ended December 31, 2020

 

(EUR thousand)

 

Biopharmaceutical
and Diagnostic
Solutions

 

 

Engineering

 

 

Total
segments

 

 

Adjustments,
eliminations
and
unallocated
items

 

 

Consolidated

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

External Customers

 

 

564,931

 

 

 

97,106

 

 

 

662,037

 

 

 

 

 

 

662,037

 

Inter-Segment

 

 

1,096

 

 

 

56,327

 

 

 

57,423

 

 

 

(57,423

)

 

 

 

Total Revenues

 

 

566,027

 

 

 

153,433

 

 

 

719,460

 

 

 

(57,423

)

 

 

662,037

 

Cost of Sales

 

 

398,411

 

 

 

121,332

 

 

 

519,743

 

 

 

(51,882

)

 

 

467,861

 

Gross Profit

 

 

167,616

 

 

 

32,101

 

 

 

199,717

 

 

 

(5,541

)

 

 

194,176

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Other operating income

 

 

5,193

 

 

 

31

 

 

 

5,224

 

 

 

7

 

 

 

5,230

 

Selling and Marketing expenses

 

 

9,762

 

 

 

2,842

 

 

 

12,604

 

 

 

7,440

 

 

 

20,044

 

Research and Development expenses

 

 

12,080

 

 

 

3,056

 

 

 

15,136

 

 

 

2,254

 

 

 

17,390

 

General and Administrative expenses

 

 

48,324

 

 

 

9,641

 

 

 

57,965

 

 

 

899

 

 

 

58,863

 

Operating Profit

 

 

102,643

 

 

 

16,593

 

 

 

119,236

 

 

 

(16,127

)

 

 

103,109

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total assets

 

 

776,832

 

 

 

188,751

 

 

 

965,583

 

 

 

2,396

 

 

 

967,979

 

Total liabilities

 

 

330,624

 

 

 

109,325

 

 

 

439,949

 

 

 

217,890

 

 

 

657,839

 

 

 

 

For the year ended December 31, 2019

 

(EUR thousand)

 

Biopharmaceutical
and Diagnostic
Solutions

 

 

Engineering

 

 

Total
segments

 

 

Adjustments,
eliminations
and
unallocated
items

 

 

Consolidated

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

External Customers

 

 

455,041

 

 

 

81,498

 

 

 

536,539

 

 

 

 

 

 

536,539

 

Inter-Segment

 

 

881

 

 

 

45,625

 

 

 

46,506

 

 

 

(46,506

)

 

 

 

Total Revenues

 

 

455,922

 

 

 

127,123

 

 

 

583,045

 

 

 

(46,506

)

 

 

536,539

 

Cost of Sales

 

 

333,539

 

 

 

104,291

 

 

 

437,830

 

 

 

(39,312

)

 

 

398,518

 

Gross Profit

 

 

122,383

 

 

 

22,832

 

 

 

145,215

 

 

 

(7,194

)

 

 

138,021

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Other operating income

 

 

8,737

 

 

 

0

 

 

 

8,737

 

 

 

0

 

 

 

8,737

 

Selling and Marketing expenses

 

 

13,776

 

 

 

3,113

 

 

 

16,889

 

 

 

9,255

 

 

 

26,144

 

Research and Development expenses

 

 

5,442

 

 

 

1,549

 

 

 

6,991

 

 

 

835

 

 

 

7,826

 

General and Administrative expenses

 

 

43,167

 

 

 

8,157

 

 

 

51,324

 

 

 

(756

)

 

 

50,568

 

Operating Profit

 

 

68,735

 

 

 

10,013

 

 

 

78,748

 

 

 

(16,528

)

 

 

62,220

 

Reconciliation from Segments Operating Profit to Consolidated Profit before Tax Explanatory

The reconciliation from total segments Operating Profit to consolidated Profit Before Tax is as follows:

 

 

For the years ended December 31,

 

(EUR thousand)

 

2021

 

 

2020

 

 

2019

 

Segments Operating Profit

 

 

171,955

 

 

 

119,236

 

 

 

78,748

 

Finance income

 

 

21,709

 

 

 

14,926

 

 

 

8,006

 

Finance expense

 

 

18,808

 

 

 

21,848

 

 

 

15,250

 

Share of profit of an associate

 

 

547

 

 

 

92

 

 

 

(262

)

Inter-segment elimination

 

 

(9,730

)

 

 

(16,127

)

 

 

(16,528

)

Profit Before Tax

 

 

165,673

 

 

 

96,279

 

 

 

54,714